[
  {
    "ts": "2026-01-27T23:09:20+00:00",
    "headline": "Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Low Risk Stocks for a Retirement Stock Portfolio. Janux Therapeutics said on January 22 that it has partnered with Bristol-Myers Squibb Company (NYSE:BMY) to develop a new cancer treatment, according to Reuters. The announcement was well received by the market, with Janux shares jumping more than […]",
    "url": "https://finance.yahoo.com/news/janux-therapeutics-partners-bristol-myers-230920453.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "42dcdcf8-ac92-3ee1-a2ef-e11bebd7be93",
      "content": {
        "id": "42dcdcf8-ac92-3ee1-a2ef-e11bebd7be93",
        "contentType": "STORY",
        "title": "Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Low Risk Stocks for a Retirement Stock Portfolio. Janux Therapeutics said on January 22 that it has partnered with Bristol-Myers Squibb Company (NYSE:BMY) to develop a new cancer treatment, according to Reuters. The announcement was well received by the market, with Janux shares jumping more than […]",
        "pubDate": "2026-01-27T23:09:20Z",
        "displayTime": "2026-01-27T23:09:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/janux-therapeutics-partners-bristol-myers-230920453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/janux-therapeutics-partners-bristol-myers-230920453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JANX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]